Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM), a clinical-stage firm focused on therapies for rare genetic mitochondrial diseases, announced its participation in three upcoming healthcare conferences. These events include the Jefferies Global Healthcare Conference from November 15-17, 2022, in London, the Piper Sandler Healthcare Conference from November 29-December 1, 2022, in New York, with a fireside chat on November 30, and the LifeSci Partners Corporate Access Event from January 9-11, 2023, in San Francisco. Presentation links will be available on their website.

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at three upcoming healthcare conferences.

Jefferies Global Healthcare Conference
Date: November 15 – 17, 2022
Location: The Waldorf Hilton, London, UK

Piper Sandler Healthcare Conference
Date: November 29 – December 1, 2022
Location: Lotte New York Palace, New York, NY
Fireside Chat: November 30, 2022, at 1:30 pm ET in Holmes 2 (4^th Floor)

LifeSci Partners Corporate Access Event
Date: January 9 – 11, 2023
Location: Beacon Grand Hotel, San Francisco, CA

Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

FAQ

What is Reneo Pharmaceuticals' focus area as of November 2022?

Reneo Pharmaceuticals specializes in developing therapies for patients with rare genetic mitochondrial diseases.

When and where is Reneo Pharmaceuticals participating in the Jefferies Global Healthcare Conference?

Reneo Pharmaceuticals will participate in the Jefferies Global Healthcare Conference from November 15-17, 2022, in London, UK.

What is the schedule for the Piper Sandler Healthcare Conference involving RPHM?

Reneo Pharmaceuticals will attend the Piper Sandler Healthcare Conference from November 29 to December 1, 2022, in New York, with a fireside chat on November 30 at 1:30 pm ET.

Where is the LifeSci Partners Corporate Access Event taking place in January 2023?

The LifeSci Partners Corporate Access Event will be held from January 9-11, 2023, at the Beacon Grand Hotel in San Francisco, CA.

How can I access Reneo Pharmaceuticals' conference presentations?

Links to Reneo Pharmaceuticals' conference presentations will be posted in the Investors section of their corporate website.